Characterization of a heparin binding site on the heavy chain of factor XI
- PMID: 9813019
- DOI: 10.1074/jbc.273.47.31153
Characterization of a heparin binding site on the heavy chain of factor XI
Abstract
The glycosaminoglycan heparin enhances several reactions involving coagulation factor XI (FXI) including activation of FXI by factor XIIa, thrombin, and autoactivation; and inactivation of activated FXI (FXIa) by serine protease inhibitors. We examined the effect of heparin on inhibition of FXIa by the inhibitors C1-inhibitor (C1-INH) and antithrombin III (ATIII). Second order rate constants for inhibition in the absence of heparin were 1.57 x 10(3) and 0.91 x 10(3) M-1 s-1 for C1-INH and ATIII, respectively. Therapeutic heparin concentrations (0.1-1.0 units/ml) enhanced inhibition by ATIII 20-55-fold compared with 0.1-7.0-fold for C1-INH. For both inhibitors, the effect of heparin over a wide range of concentrations (10(-1) to 10(5) units/ml) produced bell-shaped curves, demonstrating that inhibition occurs by a template mechanism requiring both inhibitor and protease to bind to heparin. This implies that FXI/XIa contains structural elements that interact with heparin. Human FXI contains a sequence of amino acids (R250-I-K-K-S-K) in the apple 3 domain of the heavy chain that binds heparin (Ho, D., Badellino, K., Baglia, F., and Walsh, P. (1998) J. Biol. Chem. 273, 16382-16390). To determine the importance of this sequence to heparin-mediated reactions, recombinant FXI molecules with alanine substitutions for basic amino acids were expressed in 293 fibroblasts, and tested in heparin-dependent assays. Inhibition of FXIa by ATIII in the presence of heparin was decreased 4-fold by alanine substitution at Lys253 (A253), with smaller effects noted for mutants A255 and A252. FXI undergoes autoactivation to FXIa in the presence of heparin. The rate of autoactivation was decreased substantially for A253 with modest decreases for A255 and A252. Substituting all four charged residues in the sequence resulted in a profound decrease in autoactivation, significantly greater than for any single substitution. Relative affinity for heparin was tested by determining the concentration of NaCl required to elute FXIa from heparin-Sepharose. Wild type FXIa eluted from the column at 320 mM NaCl, whereas FXIa with multiple substitutions (A252-254 or A250-255) eluted at 230 mM NaCl. All proteins with single substitutions in charged amino acids eluted at intermediate NaCl concentrations. The data indicate that FXI/XIa must bind to heparin for optimal inhibition by ATIII and for autoactivation. Lys253 is the most important amino acid involved in binding, and Lys255 and Lys252 also have roles in interactions with heparin.
Similar articles
-
A binding site for heparin in the apple 3 domain of factor XI.J Biol Chem. 1998 Jun 26;273(26):16382-90. doi: 10.1074/jbc.273.26.16382. J Biol Chem. 1998. PMID: 9632702
-
Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.Biochemistry. 2009 Feb 24;48(7):1517-24. doi: 10.1021/bi802298r. Biochemistry. 2009. PMID: 19178150 Free PMC article.
-
Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa.J Biol Chem. 2008 Jul 4;283(27):18655-64. doi: 10.1074/jbc.M802275200. Epub 2008 Apr 25. J Biol Chem. 2008. PMID: 18441012 Free PMC article.
-
The mechanism underlying activation of factor IX by factor XIa.Thromb Res. 2014 May;133 Suppl 1(0 1):S48-51. doi: 10.1016/j.thromres.2014.03.020. Thromb Res. 2014. PMID: 24759143 Free PMC article. Review.
-
An update on factor XI structure and function.Thromb Res. 2018 Jan;161:94-105. doi: 10.1016/j.thromres.2017.10.008. Epub 2017 Oct 10. Thromb Res. 2018. PMID: 29223926 Free PMC article. Review.
Cited by
-
Investigation of the anticoagulant activity of cyclic sulfated glycosaminoglycan mimetics.Carbohydr Res. 2023 Jul;529:108831. doi: 10.1016/j.carres.2023.108831. Epub 2023 May 4. Carbohydr Res. 2023. PMID: 37209666 Free PMC article.
-
Generation and characterization of aptamers targeting factor XIa.Thromb Res. 2017 Aug;156:134-141. doi: 10.1016/j.thromres.2017.06.015. Epub 2017 Jun 9. Thromb Res. 2017. PMID: 28644959 Free PMC article.
-
Factor XI anion-binding sites are required for productive interactions with polyphosphate.J Thromb Haemost. 2013 Nov;11(11):2020-8. doi: 10.1111/jth.12414. J Thromb Haemost. 2013. PMID: 24118982 Free PMC article.
-
Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.Thromb Haemost. 2017 Apr 3;117(4):671-681. doi: 10.1160/TH16-09-0691. Epub 2017 Jan 26. Thromb Haemost. 2017. PMID: 28124063 Free PMC article.
-
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease.J Cardiovasc Dev Dis. 2022 Dec 6;9(12):437. doi: 10.3390/jcdd9120437. J Cardiovasc Dev Dis. 2022. PMID: 36547434 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical